Literature DB >> 7530857

Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection.

M Yamagishi1, M Fujiwara, H Nakamura.   

Abstract

Seventy patients with olfactory disorders following upper respiratory viral infection (URVI) were studied clinically, and the olfactory mucosa of 13 patients was biopsied using special biopsy forceps. The specimens were examined using immunohistochemical staining for neuron-specific enolase (NSE), S-100 protein (S-100), cytokeratin (CK), and proliferating cell nuclear antigen (PCNA). Although the clinical course of URVI-olfactory disorders was not very good, overall a high proportion of Alinamin intravenous injection test-positive patient's recovered their sense of smell. Immunohistochemical study of the biopsy specimens revealed a decrease in the number of olfactory receptor cells and nerve bundles. In a few cases the olfactory neuroepithelium was replaced by metaplastic squamous epithelium. Sometimes different types of degeneration were found in the same specimen. No PCNA-immunoreactivity was detected in the olfactory epithelium. The result generally correlated with the degree of degeneration of the olfactory mucosa, because regeneration of the olfactory receptor cells is suspected to be extremely slow or rare in humans. Alinamin test-positive patients had many olfactory receptor cells. These findings suggest that olfactory mucosal biopsy and the Alinamin intravenous injection test are useful methods of determining the prognosis in post-URVI olfactory disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530857

Source DB:  PubMed          Journal:  Rhinology        ISSN: 0300-0729            Impact factor:   3.681


  51 in total

Review 1.  [Examination of the sense of smell].

Authors:  T Hummel; A Hähner; M Witt; B N Landis
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

2.  Olfactory disorders: distribution according to age and gender in 3,400 patients.

Authors:  Therese Fark; Thomas Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-22       Impact factor: 2.503

3.  [Olfactory disorders and their therapy].

Authors:  A Hähner; T Hummel; B A Stuck
Journal:  HNO       Date:  2014-12       Impact factor: 1.284

4.  Murine Olfactory Bulb Interneurons Survive Infection with a Neurotropic Coronavirus.

Authors:  D Lori Wheeler; Jeremiah Athmer; David K Meyerholz; Stanley Perlman
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

5.  Transcriptional impact of organophosphate and metal mixtures on olfaction: copper dominates the chlorpyrifos-induced response in adult zebrafish.

Authors:  Fred A Tilton; Susan C Tilton; Theo K Bammler; Richard P Beyer; Patricia L Stapleton; Nathaniel L Scholz; Evan P Gallagher
Journal:  Aquat Toxicol       Date:  2011-02-02       Impact factor: 4.964

6.  Specific intranasal and central trigeminal electrophysiological responses in Parkinson's disease.

Authors:  Cécilia Tremblay; Rosa Emrich; Annachiara Cavazzana; Lisa Klingelhoefer; Moritz D Brandt; Thomas Hummel; Antje Haehner; Johannes Frasnelli
Journal:  J Neurol       Date:  2019-08-26       Impact factor: 4.849

7.  Immunohistochemical characterization of human olfactory tissue.

Authors:  Eric H Holbrook; Enming Wu; William T Curry; Derrick T Lin; James E Schwob
Journal:  Laryngoscope       Date:  2011-08       Impact factor: 3.325

8.  Transcriptional biomarkers and mechanisms of copper-induced olfactory injury in zebrafish.

Authors:  Fred Tilton; Susan C Tilton; Theo K Bammler; Richard Beyer; Frederico Farin; Patricia L Stapleton; Evan P Gallagher
Journal:  Environ Sci Technol       Date:  2008-12-15       Impact factor: 9.028

9.  Intranasal vitamin A is beneficial in post-infectious olfactory loss.

Authors:  Thomas Hummel; Katherine L Whitcroft; Gina Rueter; Antje Haehner
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-04-22       Impact factor: 2.503

Review 10.  Olfaction and anosmia in rhinosinusitis.

Authors:  Pamela Dalton
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.